



Annual General Meeting of Kuros Biosciences approves majority of resolutions

April 19, 2021

Schlieren (Zurich), Switzerland, April 19, 2021 – Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved the majority of the resolutions proposed by the Board of Directors. Two proposed resolutions relating to the grant of options to the Board of Directors and to an amendment of the Articles for an increase in the conditional capital for employee share options did not reach the required majority.

The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2020 and took note of the Reports of the Auditors. Shareholders discharged the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results and approved the cash compensation for the members of the Board and the Executive Committee.

Clemens van Blitterswijk was re-elected as Chairman and Leanna Caron, Joost de Bruijn, Scott P. Bruder and Oliver Walker were re-elected as members of the Board. Chris Fair was elected as new Board Member and as new member of the Compensation Committee and Mrs. Caron and Oliver Walker were re-elected as members of the Compensation Committee. The law firm Keller KLG, Zürich was re-elected as independent Proxy. PricewaterhouseCoopers were confirmed for another one-year term as the Company's auditor.

The Annual General Meeting further approved the adjustment to the articles of association regarding the conversion of registered shares into bearer shares as well as the capital reduction through a decrease of nominal value of shares, the latter being a technical step which does not amount to a disbursement or dividend to shareholders.

The required 2/3 majority on an increase and adjustment of the conditional share capital for Employee Participation (up to 1,200,000 registered shares with a nominal value of CHF 0.10 each) was not reached.

The Annual General Meeting took place as a virtual meeting at the Company's headquarters in Schlieren. 8,186,443 shares or 24.9% of a total of 32,811,378 shares were represented.

About Kuros Biosciences AG

Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros's bone graft substitute, MagnetOs, is commercialized in the U.S. and UK for use in posterolateral spinal fusions. Kuros's lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has entered into a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S. The Company is listed according to the International Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:

Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com

LifeSci Advisors
Mary-Ann Chang
Investors
+44 7483 284 853
mchang@lifesciadvisors.com